CMPX Stock — Compass Therapeutics, Inc.

Compass Therapeutics, Inc. (CMPX)

Updated October 16, 2026.

CMPX is a Stock. Total return is -78.5% over the past 38.1 years.

Compass Therapeutics is a clinical-stage biopharmaceutical company developing antibody-based cancer therapies, with its lead candidate tovecimig designed to inhibit tumor blood vessel formation and a pipeline including checkpoint inhibitor and immune-stimulating antibody programs. The company does not currently have an established distribution schedule. This security appeals to investors with high risk tolerance who are interested in early-stage oncology drug development.

CMPX performance

Price and return data through 2026-10-16.

Total return is -78.5% over the past 38.1 years. Over the past year its total return — price change plus distributions reinvested — is -81.0%. Its deepest 1-year drawdown was 87.2%.

CMPX key facts

Asset type

Stock

Asset class

Equity

Inception date

09/16/1988

Distribution frequency

None

Last close

$0.86 (as of 2026-10-16)

Market cap

$154,875,607

Average volume

2038922.0

Beta

0.914

Payout ratio

0.0%

EPS

$-0.39

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CMPX risks and drawbacks

The deepest 1-year drawdown on record here is 87.2%.

Who may consider CMPX — and who may not

It is a weaker fit for investors who need monthly cash flow (CMPX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CMPX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions